Actively Recruiting
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-11
100
Participants Needed
8
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
CONDITIONS
Official Title
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with relapsed or refractory multiple myeloma and receiving a commercially available bispecific antibody
- Have received at least 1 but no more than 4 cycles of bispecific antibody treatment
- Male or female aged 18 years or older at the time of consent
- ECOG performance status of 3 or less
- Life expectancy greater than 12 months
You will not qualify if you...
- Received hematopoietic stem cell transplantation within 3 months before enrollment
- Planned chimeric antigen receptor T-cell therapy within the next 6 months
- More than 1 major deep-seated infection within the preceding 3 months
- Diagnosed with HIV infection, active hepatitis C virus, or active hepatitis B virus infection
- Pregnant
- Neutrophil count less than 500 x 10^9 per mL or platelet count less than 30 x 10^9 per mL
- History of cancer other than multiple myeloma in the last 3 years requiring active chemotherapy or radiation
- Known allergy or reaction to immunoglobulin G products
- Intracranial hemorrhage or embolic cerebrovascular accident in the last 6 months
- Hyperproteinemia
- Protein-losing enteropathy
- Creatinine clearance less than 30 ml/min
- Documented progression on bispecific antibody therapy
- Known history of hyperprolinemia
- Received intravenous immunoglobulin therapy within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States, 10065
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Mount Sinai Hospital
New York, New York, United States, 10029
Not Yet Recruiting
7
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
8
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
Z
Zainab Shahid, MBBS
CONTACT
S
Sergio Giralt, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here